Oil prices exceed $100, data vacuum: Silent standoff before the Federal Reserve decision
智通财经2026/09/14 09:53- The U.S. economic calendar is light, with market focus shifting to crude oil, geopolitics, U.S. Treasury yields, and the Federal Reserve's position management.
- The situation in the Middle East may dominate trading, as any disruption to major energy channels makes the market highly sensitive, and crude oil has already surpassed $100.
- Rising oil prices are fueling inflation concerns, subsequently pushing up U.S. Treasury yields and ultimately exerting pressure on equities—this transmission chain is currently driving asset pricing.
- Canada's CPI is the only important macroeconomic data today; if inflation unexpectedly deviates from forecasts, the impact could spill over into global bond markets, as investors remain extremely sensitive to inflation and central bank policy.
- The U.S. Treasury will auction 13-week and 26-week Treasury bills. With yields elevated, demand quality is worth watching, even though shorter-term maturities are less market-sensitive than longer maturities.
- No important Federal Reserve speeches are scheduled before this week’s FOMC meeting. The meeting begins on Tuesday, with the rate decision announced Wednesday at 2:00 p.m.; watch the 2-year and 10-year yields, the U.S. dollar, and rate pricing.
- There is no EIA inventory report today; crude oil will mainly trade around Middle East supply risks and geopolitical news.
- After the market closes, Kestra Medical and Dave & Buster’s will release their earnings reports, but neither is expected to serve as a catalyst for index-level moves.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bayan Resources and its subsidiaries declare force majeure on coal supply agreements
MoffettNathanson raises SpaceX target price to $142
Survival Nearly Doubles! BioNTech (BNTX.US) Lung Cancer Candidate Drug PRESERVE-003 Achieves Success in Late-Stage Trial, Providing Critical Support for Oncology Transformation
BioNTech (BNTX.US) announced on Monday that a late-stage clinical trial demonstrated its candidate drug gotistobart provided a clinically meaningful overall survival benefit compared to standard therapy in a specific type of lung cancer.
Crypto prices
More
